Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alison J Moskowitz

Showing results (41-50 of 91) with videos related to

Pageof 10
Sort By:
Clinical Lymphoma, Myeloma & Leukemia|September 10, 2025
Skin Response to Mogamulizumab in Patients With Mycosis Fungoides and Sezary Syndrome: A Retrospective, Real World CohortRachel E Christensen, Robert Stuver, Stephen Dusza, et al.
British Journal of Haematology|July 6, 2016
Risk factors predicting outcomes for primary refractory hodgkin lymphoma patients treated with salvage chemotherapy and autologous stem cell transplantationGunjan L Shah, Joachim Yahalom, Matthew J Matasar, et al.
Blood Advances|September 18, 2023
Prognostic model using 18F-FDG PET radiomics predicts progression-free survival in relapsed/refractory Hodgkin lymphomaJulia Driessen, Gerben J C Zwezerijnen, Heiko Schöder, et al.
British Journal of Haematology|March 18, 2011
Autologous stem cell transplant for early relapsed/refractory Hodgkin lymphoma: results from two transplant centresStephen D Smith, Craig H Moskowitz, Robert Dean, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 10, 2019
Nivolumab Combined With Brentuximab Vedotin for Relapsed/Refractory Primary Mediastinal Large B-Cell Lymphoma: Efficacy and Safety From the Phase II CheckMate 436 StudyPier Luigi Zinzani, Armando Santoro, Giuseppe Gritti, et al.
Blood Advances|June 23, 2023
Nivolumab combined with brentuximab vedotin for R/R primary mediastinal large B-cell lymphoma: a 3-year follow-upPier Luigi Zinzani, Armando Santoro, Giuseppe Gritti, et al.
Leukemia & Lymphoma|November 30, 2017
Outcome of children and adolescents with relapsed Hodgkin lymphoma treated with high-dose therapy and autologous stem cell transplantation: the Memorial Sloan Kettering Cancer Center experienceLisa Giulino-Roth, Tara O'Donohue, Zhengming Chen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 19, 2012
Phase II study of bendamustine in relapsed and refractory Hodgkin lymphomaAlison J Moskowitz, Paul A Hamlin, Miguel-Angel Perales, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|January 7, 2022
The Impact of Semiautomatic Segmentation Methods on Metabolic Tumor Volume, Intensity, and Dissemination Radiomics in <sup>18</sup>F-FDG PET Scans of Patients with Classical Hodgkin LymphomaJulia Driessen, Gerben J C Zwezerijnen, Heiko Schöder, et al.
Blood|December 21, 2011
Normalization of pre-ASCT, FDG-PET imaging with second-line, non-cross-resistant, chemotherapy programs improves event-free survival in patients with Hodgkin lymphomaCraig H Moskowitz, Matt J Matasar, Andrew D Zelenetz, et al.
Pageof 10

Showing results (41-50 of 91) with videos related to

Sort By:
Pageof 10
Clinical Lymphoma, Myeloma & Leukemia|September 10, 2025
Skin Response to Mogamulizumab in Patients With Mycosis Fungoides and Sezary Syndrome: A Retrospective, Real World CohortRachel E Christensen, Robert Stuver, Stephen Dusza, et al.
British Journal of Haematology|July 6, 2016
Risk factors predicting outcomes for primary refractory hodgkin lymphoma patients treated with salvage chemotherapy and autologous stem cell transplantationGunjan L Shah, Joachim Yahalom, Matthew J Matasar, et al.
Blood Advances|September 18, 2023
Prognostic model using 18F-FDG PET radiomics predicts progression-free survival in relapsed/refractory Hodgkin lymphomaJulia Driessen, Gerben J C Zwezerijnen, Heiko Schöder, et al.
British Journal of Haematology|March 18, 2011
Autologous stem cell transplant for early relapsed/refractory Hodgkin lymphoma: results from two transplant centresStephen D Smith, Craig H Moskowitz, Robert Dean, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 10, 2019
Nivolumab Combined With Brentuximab Vedotin for Relapsed/Refractory Primary Mediastinal Large B-Cell Lymphoma: Efficacy and Safety From the Phase II CheckMate 436 StudyPier Luigi Zinzani, Armando Santoro, Giuseppe Gritti, et al.
Blood Advances|June 23, 2023
Nivolumab combined with brentuximab vedotin for R/R primary mediastinal large B-cell lymphoma: a 3-year follow-upPier Luigi Zinzani, Armando Santoro, Giuseppe Gritti, et al.
Leukemia & Lymphoma|November 30, 2017
Outcome of children and adolescents with relapsed Hodgkin lymphoma treated with high-dose therapy and autologous stem cell transplantation: the Memorial Sloan Kettering Cancer Center experienceLisa Giulino-Roth, Tara O'Donohue, Zhengming Chen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 19, 2012
Phase II study of bendamustine in relapsed and refractory Hodgkin lymphomaAlison J Moskowitz, Paul A Hamlin, Miguel-Angel Perales, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|January 7, 2022
The Impact of Semiautomatic Segmentation Methods on Metabolic Tumor Volume, Intensity, and Dissemination Radiomics in <sup>18</sup>F-FDG PET Scans of Patients with Classical Hodgkin LymphomaJulia Driessen, Gerben J C Zwezerijnen, Heiko Schöder, et al.
Blood|December 21, 2011
Normalization of pre-ASCT, FDG-PET imaging with second-line, non-cross-resistant, chemotherapy programs improves event-free survival in patients with Hodgkin lymphomaCraig H Moskowitz, Matt J Matasar, Andrew D Zelenetz, et al.
Pageof 10